Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 23Breast Carcinoma In Situ 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Inflammatory Breast Neoplasms 1Endometrial Neoplasms 1Cardiotoxicity 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Metastatic 1Barrett Esophagus 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Doxorubicin 5Cyclophosphamide 3Trastuzumab 2Docetaxel 2Dexrazoxane 2empagliflozin 1Taxes 1Tamoxifen 1Razoxane 1Radiotherapy 1Radiation 1Paclitaxel 1Neoadjuvant Therapy 1Methotrexate 1Metformin 1Leucovorin 1High-Intensity Interval Training 1Hematologic Tests 1Filgrastim 1Exercise 1Epirubicin 1Echocardiography 1Cisplatin 1Chemotherapy, Adjuvant 1Carvedilol 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cardiotoxicity × Tamoxifen × Clear all
NCT00016276 2013-01-16

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
396 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡